SCHEMBL5456931

SCHEMBL5456931

COc1ccc(CNc2ccc(CC(=O)N3CCc4c(OC)ccc(N5CCN(C)CC5)c4C3)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.50
ABCB1 P08183 1/20 0.48
ABCC1 P33527 1/20 0.48
HTR1A P08908 4/20 0.44
HTR1D P28221 4/20 0.44
HTR1B P28222 4/20 0.44
GFER P55789 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ALDH1A1 P00352 3/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NPC1 O15118 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
RAB9A P51151 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5456835 0.93 NPC1 (0.49) MAPTHTR1AHTR1DHTR1BGFER
SCHEMBL5446341 0.92 MAPT (0.59) MAPTABCB1ABCC1HTR1AHTR1D
SCHEMBL5452185 0.91 HTR1A (0.46) MAPTABCB1ABCC1HTR1AHTR1D
SCHEMBL5452393 0.90 MAPT (0.51) MAPTABCB1ABCC1HTR1AHTR1D
SCHEMBL5450240 0.88 KDM4E (0.45) MAPTHTR1AHTR1DHTR1BALDH1A1
SCHEMBL5455125 0.87 LMNA (0.51) MAPTABCB1ABCC1HTR1ASMN1; SMN2
SCHEMBL14596914 0.87 ALDH1A1 (0.49) MAPTABCB1ABCC1HTR1AHTR1D
SCHEMBL5445105 0.86 HTR1A (0.42) MAPTABCB1ABCC1HTR1AHTR1D
SCHEMBL5453639 0.85 NPC1 (0.48) HTR1AHTR1DHTR1BKMT2ANPC1
SCHEMBL5449891 0.84 GFER (0.47) MAPTABCB1ABCC1HTR1AHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020183011-A1 HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER INSTITUT CURIE (FR) 2020-09-17 WO disclosed
US-20070010526-A1 Therapeutic isoquinoline compounds ASTRAZENECA AB (SE) 2007-01-11 US disclosed
US-20070010526-A1 Therapeutic isoquinoline compounds ASTRAZENECA AB (SE) 2007-01-11 US disclosed
US-20070010526-A1 Therapeutic isoquinoline compounds ASTRAZENECA AB (SE) 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010526-A1 Therapeutic isoquinoline compounds HTR1B, HTR1D, HTR1A MAPT 577/4885ABCB1 2319/4885ABCC1 3005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.